[1] MAWRI S, MICHAELS A, GIBBS J, et al. CRT-100.78 ACE inhibitors and ARBs in post-percutaneous coronary intervention contrast-induced nephropathy (CIN): to hold or not to hold? JACC: Cardiovasc Interv,2018,11(4):S22.
[2] VACHHARAJANI T, HOSSAIN M, COSTANZO E, et al. Contrast-Induced nephropathy: Pathophysiology, risk factors, and prevention[J]. Saudi J Kidney Dis Transpl,2018,29(1):1. doi:  10.4103/1319-2442.225199
[3] KODZWA R. ACR manual on contrast media: 2018 updates[J]. Radiol Technol,2019,91(1):97-100.
[4] JO S H, LEE J M, PARK J, et al. The impact of renin-angiotensin-aldosterone system blockade on contrast-induced nephropathy: a meta-analysis of 12 studies with 4, 493 patients[J]. Cardiology,2015,130(1):4-14. doi:  10.1159/000366473
[5] CHEN Y T, CHAN C K, LI W Y, et al. Renin-angiotensin-aldosterone system inhibition decreased contrast-associated acute kidney injury in chronic kidney disease patients[J]. J Formos Med Assoc,2021,120(1):641-650. doi:  10.1016/j.jfma.2020.07.022
[6] WOLAK T, ALIEV E, ROGACHEV B, et al. Renal safety and angiotensin II blockade medications in patients undergoing non-emergent coronary angiography: a randomized controlled study[J]. Isr Med Assoc J,2013,15(11):682-687.
[7] ROSENSTOCK J L, BRUNO R, KIM J K, et al. The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast-induced nephropathy[J]. Int Urol Nephrol,2008,40(3):749-755. doi:  10.1007/s11255-008-9368-1
[8] ROSADO INGELMO A, DOÑA DIAZ I, CABAÑAS MORENO R, et al. Clinical practice guidelines for diagnosis and management of hypersensitivity reactions to contrast media[J]. J Investig Allergol Clin Immunol,2016,26(3):144-155; quiz2pfollowing155. doi:  10.18176/jiaci.0058
[9] 李飞, 杨定平. 对比剂肾病的发病机制及防治[J]. 临床肾脏病杂志, 2013, 13(9):426-429.
[10] 陈彩玲, 黄铮, 赖雯苑, 等. ACEI/ARB与CCB防治高血压病伴慢性肾功能不全患者发生造影剂肾病的效果比较[J]. 心脏杂志, 2015, 27(6):703-707.
[11] OGUZHAN N, CILAN H, SIPAHIOGLU M, et al. The lack of benefit of a combination of an angiotensin receptor blocker and calcium channel blocker on contrast-induced nephropathy in patients with chronic kidney disease[J]. Ren Fail,2013,35(4):434-439. doi:  10.3109/0886022X.2013.766566
[12] 王仁秀, 姜松, 解秀芬, 等. 经皮冠状动脉介入治疗后并发造影剂肾病危险因素的Meta分析[J]. 实用心脑肺血管病杂志, 2020, 28(9):74-80. doi:  10.3969/j.issn.1008-5971.2020.09.015
[13] MOLEN A J, REIMER P, DEKKERS I A, et al. Post-contrast acute kidney injury - Part 1: Definition, clinical features, incidence, role of contrast medium and risk factors[J]. Eur Radiol,2018,28(7):2845-2855. doi:  10.1007/s00330-017-5246-5
[14] 王琼涛, 吉六舟, 张进锋, 等. 冠心病患者经皮冠状动脉介入术后发生造影剂肾病的危险因素[J]. 中华实用诊断与治疗杂志, 2019, 33(11):1078-1081.
[15] WANG M, ZHANG L, YUE R Z, et al. Significance of cystatin C for early diagnosis of contrast-induced nephropathy in patients undergoing coronary angiography[J]. Med Sci Monit,2016,22:2956-2961. doi:  10.12659/MSM.897241
[16] DAVENPORT M S, PERAZELLA M A, YEE J, et al. Use of intravenous iodinated contrast media in patients with kidney disease: consensus statements from the American college of radiology and the national kidney foundation[J]. Kidney Med,2020,2(1):85-93. doi:  10.1016/j.xkme.2020.01.001